Physician profile
Imran Ahmad
NPI 1689889511
$1,408.69
in general payments reported to CMS, 2019-2025
30 companies · $368 in 2025
The $368 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $216 · 2021: $144 · 2022: $48.34 · 2023: $73.44 · 2024: $112 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $227.86 | 2019-2023 | Xarelto |
| Vifor Pharma, INC. | $128.52 | 2019-2021 | |
| Novo Nordisk INC | $96.72 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $94.62 | 2019 | |
| Madrigal Pharmaceuticals | $64.23 | 2025 | Rezdiffra |
| Advanced Respiratory, INC | $61.41 | 2019 | |
| Stryker Corporation | $61.13 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $59.96 | 2019-2025 | Airsupra |
| Mylan Specialty L.P. | $52.09 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.20 | 2021-2023 | Lifevest |
| Baxter Healthcare | $41.24 | 2025 | Hillrom - Monarch Airway Clearance System |
| Pfizer INC. | $36.34 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.41 | 2024-2025 | Xifaxan |
| Cumberland Pharmaceuticals, INC. | $32.04 | 2019-2024 | Sancuso |
| Gilead Sciences, INC. | $29.08 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.38 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $26.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2020 | |
| Abbvie INC. | $24.44 | 2025 | |
| Sk Life Science, INC. | $24.04 | 2020 | |
| Ucb, INC. | $23.92 | 2019 | |
| Lundbeck LLC | $23.60 | 2025 | Rexulti |
| Astellas Pharma US INC | $23.45 | 2023 | Cresemba |
| Exact Sciences Corporation | $23.13 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $22.65 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.29 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $21.81 | 2021 | |
| Heartflow, INC. | $19.75 | 2025 | |
| Neurelis, INC. | $17.22 | 2025 | Valtoco |
| Tetraphase Pharmaceuticals, INC. | $15.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.